The studies with SGLT-2 inhibitors showed a variable 3% to 14% relative risk reductions for major adverse cardiovascular events (MACE) and a consistent ∼30% relative risk reductions for hospitalization for heart failure across individual drugs [132-135]. Here, SLC5A2 is linked to heart failure.